Publication Topic

Ierardi AM, Burns A, Urban A, Finley B. 2024. A risk assessment of cosmetic talc for the development of mesothelioma and ovarian cancer. Chapter 13 in: Paustenbach DJ (ed), Human and Ecological Risk Assessment: Theory and Practice, Third Edition. Wiley, ISBN: 978-1-119-74296-8, pp. 541–570.

Vincent M, Fitch S, Bylsma L, Thompson C, Rogers S, Britt J, Wikoff D. Integration of toxicological and epidemiological information to evaluate biological plausibility and causality of associations between inhaled formaldehyde (FA) and lymphohematopoietic (LHP) cancers. Abstract 5157, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024. 

Allen B, Vincent M, Lipworth L, Panko J, Suh M, Jiang X, Mumma MT, Proctor D. Lung cancer risk and exposure to hexavalent chromium: Results of extended mortality study of workers with low level exposures and quantitative risk assessment using pooled analysis of three cohorts. Poster presentation at Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Thompson CM, Heintz MM, Cullen JM, Haws LC. 2024. Letter to the Editor of Environmental Pollution: In regard to Wan et al. (2024), “GenX caused liver injury and potential hepatocellular carcinoma of mice via drinking water even at environmental concentration.” Environ Pollut 355(Aug 15):124171; doi: 10.1016/j.envpol.2024.1241741. PMID: 38776993.

Yoshino T, Hooda N, Younan D, Shitara K, Heinemann V,…, Suh M, Reichert H, et al. A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness. Abstract 127P, European Society for Medical Oncology (ESMO) Asia Congress. Ann Oncol 34(Sup 4):S1519; doi: 10.1016/j.annonc.2023.10.262. Singapore, December 2023.

Bylsma LC, Pundole X, Ju C-H, Hooda N, Movva N, Elkhouly E, et al. 2023. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. Target Oncol 18(6):821-835; doi: 10.1007/s11523-023-01008-x. PMID: 37930513.

Thompson CM, Kirman C, Harris MA. 2023. Derivation of oral cancer slope factors for hexavalent chromium informed by pharmacokinetic models and in vivo genotoxicity data. Regul Toxicol Pharmacol 145(Dec):105521; doi: 10.1016/j.yrtph.2023.105521. PMID: 37863416.

Wikoff D, Thompson C, Vincent M, Fitch S, Britt J, Reichert H, Rogers S. 2023. Protocol for the systematic review of formaldehyde and lymphohematopoietic (LHP) cancers. OSF | Protocol_Formaldehyde and LHP SR.pdf.

Pundole X, Ju C-H, Bylsma LC, Hooda N, Movva N, Elkhouly E, Bebb DG, Fryzek J, et al. Prevalence of delta-like ligand 3 expression in small cell lung cancer. Abstract e20618, J Clin Oncol 41(16 Sup):e20618; doi: 10.1200/JCO.2023.41.16_suppl.e20618. 2023 ASCO Annual Meeting, Chicago IL, June 2023.

Dalvi T, Nørgaard M, Fryzek JP, Movva N, Pedersen L, Hansen HP, et al. 2023. Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark. PLoS ONE 18(4):e0284037; doi: 10.1371/journal.pone.0284037. PMID: 37040387.

Heintz MM, Haws LC, Klaunig JE, Cullen JM, Thompson CM. 2023. Assessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans. Toxicol Sci 192(1):15–29; doi: 10.1093/toxic/kfad004. PMID: 36629480.

Leslie TF, Frankenfeld CL, Menon N. 2022. Disparities in colorectal cancer time-to-treatment and survival time associated with racial and economic residential segregation surrounding the diagnostic hospital, Georgia 2010–2015. Cancer Epidemiol 81(Dec):102267; doi: 10.1016/j.canep.2022.102267. PMID: 36166941.

View Abstract

Suh M, Cloud M, Balasubramanian A, Movva N, Fryzek J, Cohen S. 2022. A systematic literature review (SLR) of MTAP deletions in multiple solid and hematologic cancers. PROSPERO 2022 CRD42022354037.

Gupta N, Patel HD, Taylor J, Borin JF, Jacobsohn K,…, Price C, et al. 2022. Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes. Prostate Cancer Prostatic Dis 25(3):444–452; doi: 10.1038/s41391-022-00553-2. PMID: 35790788.

Schenfeld J, Gong T, Henry D, Kelsh M, Gawade P, Peng Y, Bradbury BD, Li S. 2022. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 30(7):6327–6338; doi: 10.1007/s00520-022-06967-x. PMID: 35482126.

Gillezeau C, Movva N, van Gerwen M, Rabon-Stith K, Shire N, Brohawn PZ, Taioli E, Fryzek J. 2022. Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients. PLoS One 17(8):e0271339; doi: 10.1371/journal.pone.0271339. PMID: 36040901.

Bylsma L, Fryzek J, Movva N, Frankenfeld C, Hooda N, Pundole X, et al. 2022. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. PROSPERO 2022 CRD42022351119

Tsvetkov L, Pittsenbarger J, Atsriku C, Devine P, Dingley K, et al. 2022. Inhibition of CDC7 with Sgr-2921 in AML models results in enhanced DNA damage and anti-leukemic activity as monotherapy and in combination with standard of care agents. Blood 140 (Sup 1):5961–5962; doi: 10.1182/blood-2022-167239.

Danese MD, Schenfeld J, Shaw J, Gawade P, Balasubramanian A, Kelsh M, et al. 2022. Association between granulocyte colony-stimulating factor (G-CSF) use and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) among elderly patients with breast, lung, or prostate cancer. Adv Ther 39(6):2778–2795; doi:10.1007/s12325-022-02141-1. PMID: 35430673.

Anneberg M, Svane HML, Fryzek J, Nicholson G, White JB, Edris B, Smith LM, Hooda N, et al. 2022. The epidemiology of desmoid tumors in Denmark. Cancer Epidemiol 77(April):102114; doi: 10.1016/j.canep.2022.102114. PMID: 35121405.